Adia Nutrition has formed a strategic partnership with a clinic in Atlanta to supply regenerative products for a new Autism Spectrum Disorder (ASD) clinical study. The study will test AdiaVita, a stem cell-rich product derived from umbilical cord blood, on 100 participants to explore its potential to reduce inflammation and improve autism symptoms. This collaboration supports Adia Nutrition's 2026 goal to build scientific evidence for regenerative therapies and aims to pave the way for insurance coverage of such treatments. Meanwhile, Adia Med in Winter Park is also recruiting for its own autism study starting May 2026, demonstrating the company's strong commitment to advancing autism research.
Purecore Metals Inc. has signed a non-binding letter of intent with Skyharbour Resources to acquire an option to earn up to 100% interest in the Yurchison uranium property in Saskatchewan's Athabasca Basin. The property covers over 35,000 hectares an...
Shirofune has introduced Walmart Connect, an integration that allows advertisers and agencies to manage Walmart retail media campaigns alongside other digital channels within a single platform. This automation reduces manual bid adjustments and repor...
Point completed a $508.6 million rated asset-backed securitization of its Home Equity Investment (HEI) assets, marking the largest transaction ever in the HEI asset class. The deal attracted over 30 institutional investors and priced at significantly...
The global reactive hot melt adhesives market is projected to grow from $2.02 billion in 2025 to $4.29 billion by 2035, at a CAGR of 7.72%. Growth is driven by regulations limiting solvent-based adhesives, increased use of polyurethane adhesives in a...
Red Light Holland, after acquiring Filament Health, has expanded its capabilities in pharmaceutical-grade psilocybin development. Filament completed a shipment of its botanical psilocybin drug candidate, PEX010, to the European Union to support multi...
